1.Zawadzki, JK, Dunaif, A. Diagnostic Criteria for Polycystic Ovary Syndrome: towards a rational approach. Boston: Blackwell Scientific Publications, 1992.
2.Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81(1):19–25.
3.Azziz, R, Carmina, E, Dewailly, D, et al. The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91(2):456–488.
4.March, WA, Moore, VM, Willson, KJ, Phillips, DI, Norman, RJ, Davies, MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010;25(2):544–551.
5.Vink, JM, Sadrzadeh, S, Lambalk, CB, Boomsma, DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab 2006;91(6):2100–2104.
6.Legro, RS, Arslanian, SA, Ehrmann, DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013;98(12):4565–4592.
7.Panidis, D, Tziomalos, K, Macut, D, et al. Cross-sectional analysis of the effects of age on the hormonal, metabolic, and ultrasonographic features and the prevalence of the different phenotypes of polycystic ovary syndrome. Fertil Steril 2012;97(2):494–500.
8.Liou, TH, Yang, JH, Hsieh, CH, Lee, CY, Hsu, CS, Hsu, MI. Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women. Fertil Steril 2009;92(6):1960–1965.
9.Goodman, NF, Bledsoe, MB, Cobin, RH, et al. American Association of Clinical Endocrinologists medical guidelines for the clinical practice for the diagnosis and treatment of hyperandrogenic disorders. Endocr Pract 2001;7(2):120–134.
10.Ferriman, D, Gallwey, JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440–1447.
11.Martin, KA, Chang, RJ, Ehrmann, DA, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(4):1105–1120.
12.Ibanez, L, Potau, N, Francois, I, de Zegher, F. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: Relation to reduced fetal growth. J Clin Endocrinol Metab 1998;83(10):3558–3562.
13.Guzel, AI, Kuyumcuoglu, U, Celik, Y. Factors affecting the degree of hirsutism in patients with polycystic ovary syndrome. Arch Gynecol Obstet 2012;285(3):767–770.
14.Bhattacharya, SM, Ghosh, M. Insulin resistance and adolescent girls with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2010;23(3):158–161.
15.Torvinen, A, Koivunen, R, Pouta, A, et al. Metabolic and reproductive characteristics of first-degree relatives of women with self-reported oligo-amenorrhoea and hirsutism. Gynecol Endocrinol 2011;27(9):630–635.
16.Cela, E, Robertson, C, Rush, K, et al. Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol 2003;149(5):439–442.
17.Vexiau, P, Chaspoux, C, Boudou, P, et al. Role of androgens in female-pattern androgenetic alopecia, either alone or associated with other symptoms of hyperandrogenism. Arch Dermatol Res 2000;292(12):598–604.
18.Shi, Y, Guo, M, Yan, J, et al. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome. Neuro Endocrinol Lett 2007;28(6):807–810.
19.Brown, ZA, Louwers, YV, Fong, SL, et al. The phenotype of polycystic ovary syndrome ameliorates with aging. Fertil Steril 2011;96(5):1259–1265.
20.Bronstein, J, Tawdekar, S, Liu, Y, Pawelczak, M, David, R, Shah, B. Age of onset of polycystic ovarian syndrome in girls may be earlier than previously thought. J Pediatr Adolesc Gynecol 2011;24(1):15–20.
21.Elting, MW, Korsen, TJ, Rekers-Mombarg, LT, Schoemaker, J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod 2000;15(1):24–28.
22.Carmina, E, Campagna, AM, Lobo, RA. A 20-year follow-up of young women with polycystic ovary syndrome. Obstet Gynecol 2012;119(2 Pt 1):263–269.
23.Dahlgren, E, Johansson, S, Lindstedt, G, et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 1992;57(3):505–513.
24.Nazir, F, Tasleem, H, Tasleem, S, Sher, Z, Waheed, K. Polycystic ovaries in adolescent girls from Rawalpindi. J Pak Med Assoc 2011;61(10):961–963.
25.Sam, S, Legro, RS, Essah, PA, Apridonidze, T, Dunaif, A. Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc Natl Acad Sci USA 2006;103(18):7030–7035.
26.Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation 2002; 106(25): 3143–3421.
27.Grundy, SM, Cleeman, JI, Daniels, SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005;112(17):2735–2752.
28.Moran, LJ, Misso, ML, Wild, RA, Norman, RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010;16(4):347–363.
29.Rahmanpour, H, Jamal, L, Mousavinasab, SN, Esmailzadeh, A, Azarkhish, K. Association between polycystic ovarian syndrome, overweight, and metabolic syndrome in adolescents. J Pediatr Adolesc Gynecol 2012;25(3):208–212.
30.Ehrmann, DA, Liljenquist, DR, Kasza, K, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91(1):48–53.
31.Lord, J, Thomas, R, Fox, B, Acharya, U, Wilkin, T. The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome. BJOG 2006;113(10):1203–1209.
32.Palep-Singh, M, Picton, HM, Barth, JH, Balen, AH. Ethnic variations in the distribution of obesity and biochemical metabolic abnormalities in fertility clinic attendees. J Reprod Med 2008;53(2):117–123.
33.Guo, M, Chen, ZJ, Macklon, NS, et al. Cardiovascular and metabolic characteristics of infertile Chinese women with PCOS diagnosed according to the Rotterdam consensus criteria. Reprod Biomed Online 2010;21(4):572–580.
34.Castelo-Branco, C, Steinvarcel, F, Osorio, A, Ros, C, Balasch, J. Atherogenic metabolic profile in PCOS patients: role of obesity and hyperandrogenism. Gynecol Endocrinol 2010;26(10):736–742.
35.Wild, RA, Carmina, E, Diamanti-Kandarakis, E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010;95(5):2038–2049.
36.Ehrmann, DA, Kasza, K, Azziz, R, Legro, RS, Ghazzi, MN, PCOS/Troglitazone Study Group. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90(1):66–71.
37.Escobar-Morreale, HF, Luque-Ramirez, M, San Millan, JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 2005;26(2):251–282.
38.Yildiz, BO, Knochenhauer, ES, Azziz, R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93(1):162–168.
39.Gambineri, A, Pelusi, C, Vicennati, V, Pagotto, U, Pasquali, R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 2002;26(7):883–896.
40.Wehr, E, Moller, R, Horejsi, R, et al. Subcutaneous adipose tissue topography and metabolic disturbances in polycystic ovary syndrome. Wien Klin Wochenschr 2009;121(7–8):262–269.
41.Lo, JC, Feigenbaum, SL, Escobar, GJ, Yang, J, Crites, YM, Ferrara, A. Increased prevalence of gestational diabetes mellitus among women with diagnosed polycystic ovary syndrome: a population-based study. Diabetes Care 2006;29(8):1915–1917.
42.Coviello, AD, Sam, S, Legro, RS, Dunaif, A. High prevalence of metabolic syndrome in first-degree male relatives of women with polycystic ovary syndrome is related to high rates of obesity. J Clin Endocrinol Metab 2009;94(11):4361–4366.
43.Trottier, A, Battista, MC, Geller, DH, et al. Adipose tissue insulin resistance in peripubertal girls with first-degree family history of polycystic ovary syndrome. Fertil Steril 2012;98(6):1627–1634.
44.Shaw, LJ, Bairey Merz, CN, Azziz, R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health–National Heart, Lung, and Blood Institute sponsored women’s ischemia syndrome evaluation. J Clin Endocrinol Metab 2008;93(4):1276–1284.
45.Cupisti, S, Kajaia, N, Dittrich, R, Duezenli, H, W Beckmann, M, Mueller, A. Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome. Eur J Endocrinol 2008;158(5):711–719.
46.Cho, LW, Kilpatrick, ES, Keevil, BG, et al. Insulin resistance variability in women with anovulatory and ovulatory polycystic ovary syndrome, and normal controls. Horm Metab Res 2011;43(2):141–145.
47.Legro, RS, Gnatuk, CL, Kunselman, AR, Dunaif, A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 2005;90(6):3236–3242.
48.Holte, J, Gennarelli, G, Berne, C, Bergh, T, Lithell, H. Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state? Hum Reprod 1996;11(1):23–28.
49.Elting, MW, Korsen, TJ, Bezemer, PD, Schoemaker, J. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod 2001;16(3):556–560.
50.Luque-Ramirez, M, Alvarez-Blasco, F, Mendieta-Azcona, C, Botella-Carretero, JI, Escobar-Morreale, HF. Obesity is the major determinant of the abnormalities in blood pressure found in young women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92(6):2141–2148.
51.Barcellos, CR, Rocha, MP, Hayashida, SA, Mion Junior, D, Lage, SG, Marcondes, JA. Impact of body mass index on blood pressure levels in patients with polycystic ovary syndrome. Arq Bras Endocrinol Metabol 2007;51(7):1104–1109.
52.Tasali, E, Van Cauter, E, Ehrmann, DA. Relationships between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91(1):36–42.
53.de Sousa, G, Schluter, B, Menke, T, Trowitzsch, E, Andler, W, Reinehr, T. A comparison of polysomnographic variables between adolescents with polycystic ovarian syndrome with and without the metabolic syndrome. Metab Syndr Relat Disord 2011;9(3):191–196.
54.Toulis, KA, Goulis, DG, Mintziori, G, et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update 2011;17(6):741–760.
55.de Groot, PC, Dekkers, OM, Romijn, JA, Dieben, SW, Helmerhorst, FM. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Hum Reprod Update 2011;17(4):495–500.
56.Luque-Ramirez, M, Mendieta-Azcona, C, Alvarez-Blasco, F, Escobar-Morreale, HF. Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. Hum Reprod 2007;22(12):3197–3203.
57.Christian, RC, Dumesic, DA, Behrenbeck, T, Oberg, AL, Sheedy, PF, 2nd, Fitzpatrick, LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88(6):2562–2568.
58.Iftikhar, S, Collazo-Clavell, ML, Roger, VL, et al. Risk of cardiovascular events in patients with polycystic ovary syndrome. Neth J Med 2012;70(2):74–80.
59.Mani, H, Levy, MJ, Davies, MJ, et al. Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study. Clin Endocrinol (Oxf) 2013;78(6):926–934.
60.Brzozowska, MM, Ostapowicz, G, Weltman, MD. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. J Gastroenterol Hepatol 2009;24(2):243–247.
61.Zueff, LF, Martins, WP, Vieira, CS, Ferriani, RA. Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound Obstet Gynecol 2012;39(3):341–347.
62.Gutierrez-Grobe, Y, Ponciano-Rodriguez, G, Ramos, MH, Uribe, M, Mendez-Sanchez, N. Prevalence of non alcoholic fatty liver disease in premenopausal, postmenopausal and polycystic ovary syndrome women the role of estrogens. Ann Hepatol 2010;9(4):402–409.
63.Barfield, E, Liu, YH, Kessler, M, Pawelczak, M, David, R, Shah, B. The prevalence of abnormal liver enzymes and metabolic syndrome in obese adolescent females with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2009;22(5):318–322.
64.Kroenke, K, Spitzer, RL, Williams, JB. The patient health questionnaire-2: Validity of a two-item depression screener. Med Care 2003;41(11):1284–1292.
65.Gilbody, S, Richards, D, Brealey, S, Hewitt, C. Screening for depression in medical settings with the patient health questionnaire (PHQ): a diagnostic meta-analysis. J Gen Intern Med 2007;22(11):1596–1602.
66.Cinar, N, Kizilarslanoglu, MC, Harmanci, A, et al. Depression, anxiety and cardiometabolic risk in polycystic ovary syndrome. Hum Reprod 2011;26(12):3339–3345.
67.Hollinrake, E, Abreu, A, Maifeld, M, Van Voorhis, BJ, Dokras, A. Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertil Steril 2007;87(6):1369–1376.
68.Jones, GL, Hall, JM, Lashen, HL, Balen, AH, Ledger, WL. Health-related quality of life among adolescents with polycystic ovary syndrome. J Obstet Gynecol Neonatal Nurs 2011;40(5):577–588.
69.Barry, JA, Kuczmierczyk, AR, Hardiman, PJ. Anxiety and depression in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 2011;26(9):2442–2451.
70.Pastore, LM, Patrie, JT, Morris, WL, Dalal, P, Bray, MJ. Depression symptoms and body dissatisfaction association among polycystic ovary syndrome women. J Psychosom Res 2011;71(4):270–276.
71.Kowalczyk, R, Skrzypulec, V, Lew-Starowicz, Z, Nowosielski, K, Grabski, B, Merk, W. Psychological gender of patients with polycystic ovary syndrome. Acta Obstet Gynecol Scand 2012;91(6):710–714.
72.Stovall, DW, Scriver, JL, Clayton, AH, Williams, CD, Pastore, LM. Sexual function in women with polycystic ovary syndrome. J Sex Med 2012;9(1):224–230.
73.Dokras, A, Clifton, S, Futterweit, W, Wild, R. Increased prevalence of anxiety symptoms in women with polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 2012;97(1):225–30.e2.
74.Deeks, AA, Gibson-Helm, ME, Paul, E, Teede, HJ. Is having polycystic ovary syndrome a predictor of poor psychological function including anxiety and depression? Hum Reprod 2011;26(6):1399–1407.
75.Kerchner, A, Lester, W, Stuart, SP, Dokras, A. Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study. Fertil Steril 2009;91(1):207–212.
76.Mansson, M, Holte, J, Landin-Wilhelmsen, K, Dahlgren, E, Johansson, A, Landen, M. Women with polycystic ovary syndrome are often depressed or anxious–a case control study. Psychoneuroendocrinology 2008;33(8):1132–1138.
77.Lamb, JD, Johnstone, EB, Rousseau, JA, et al. Physical activity in women with polycystic ovary syndrome: prevalence, predictors, and positive health associations. Am J Obstet Gynecol 2011;204(4):352.e1–352.e6.
78.Thomson, RL, Buckley, JD, Lim, SS, et al. Lifestyle management improves quality of life and depression in overweight and obese women with polycystic ovary syndrome. Fertil Steril 2010;94(5):1812–1816.
79.Roos, N, Kieler, H, Sahlin, L, Ekman-Ordeberg, G, Falconer, H, Stephansson, O. Risk of adverse pregnancy outcomes in women with polycystic ovary syndrome: population based cohort study. BMJ. 2011;343:d6309.
80.Koivunen, R, Pouta, A, Franks, S, et al. Fecundability and spontaneous abortions in women with self-reported oligo-amenorrhea and/or hirsutism: Northern Finland birth cohort 1966 study. Hum Reprod 2008;23(9):2134–2139.
81.Kabiru, W, Raynor, BD. Obstetric outcomes associated with increase in BMI category during pregnancy. Am J Obstet Gynecol 2004;191(3):928–932.
82.Qin, JZ, Pang, LH, Li, MJ, Fan, XJ, Huang, RD, Chen, HY. Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol 2013;11:56.
83.Legro, RS, Barnhart, HX, Schlaff, WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356(6):551–566.
84.Boomsma, CM, Eijkemans, MJ, Hughes, EG, Visser, GH, Fauser, BC, Macklon, NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006;12(6):673–683.
85.Cocksedge, KA, Saravelos, SH, Metwally, M, Li, TC. How common is polycystic ovary syndrome in recurrent miscarriage? Reprod Biomed Online 2009;19(4):572–576.
86.Winter, E, Wang, J, Davies, MJ, Norman, R. Early pregnancy loss following assisted reproductive technology treatment. Hum Reprod 2002;17(12):3220–3223.
87.Ozgun, MT, Uludag, S, Oner, G, Batukan, C, Aygen, EM, Sahin, Y. The influence of obesity on ICSI outcomes in women with polycystic ovary syndrome. J Obstet Gynaecol 2011;31(3):245–249.
88.Hasegawa, I, Tanaka, K, Sanada, H, Imai, T, Fujimori, R. Studies on the cytogenetic and endocrinologic background of spontaneous abortion. Fertil Steril 1996;65(1):52–54.
89.Moini, A, Tadayon, S, Tehranian, A, Yeganeh, LM, Akhoond, MR, Yazdi, RS. Association of thrombophilia and polycystic ovarian syndrome in women with history of recurrent pregnancy loss. Gynecol Endocrinol 2012;28(8):590–593.
90.Reyes-Munoz, E, Castellanos-Barroso, G, Ramirez-Eugenio, BY, et al. The risk of gestational diabetes mellitus among Mexican women with a history of infertility and polycystic ovary syndrome. Fertil Steril 2012;97(6):1467–1471.
91.Palomba, S, Falbo, A, Russo, T, et al. The risk of a persistent glucose metabolism impairment after gestational diabetes mellitus is increased in patients with polycystic ovary syndrome. Diabetes Care 2012;35(4):861–867.
92.Bjercke, S, Dale, PO, Tanbo, T, Storeng, R, Ertzeid, G, Abyholm, T. Impact of insulin resistance on pregnancy complications and outcome in women with polycystic ovary syndrome. Gynecol Obstet Invest 2002;54(2):94–98.
93.Hizli, D, Kosus, A, Kosus, N, Kamalak, Z, Ak, D, Turhan, NO. The impact of birth weight and maternal history on acne, hirsutism, and menstrual disorder symptoms in Turkish adolescent girls. Endocrine 2012;41(3):473–478.
94.McDonald, SD, Han, Z, Mulla, S, et al. Preterm birth and low birth weight among in vitro fertilization singletons: a systematic review and meta-analyses. Eur J Obstet Gynecol Reprod Biol 2009;146(2):138–148.
95.Barry, JA, Azizia, MM, Hardiman, PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2014;20(5):748–758.
96.Pierpoint, T, McKeigue, PM, Isaacs, AJ, Wild, SH, Jacobs, HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998;51(7):581–586.
97.Witchel, SF, Azziz, R. Nonclassic congenital adrenal hyperplasia. Int J Pediatr Endocrinol 2010;2010:625105.
98.Bahn, RS, Burch, HB, Cooper, DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 2011;17(3):456–520.
99.Garber, JR, Cobin, RH, Gharib, H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract 2012;18(6):988–1028.
100.Neraud, B, Dewailly, D. Drug-induced hyperandrogenism. In: Azziz, R, Nestler, JE, Dewailly, D, eds. Contemporary Endocrinology: Androgen Excess Disorders in Women, Polycystic Ovarian Syndrome and Other Disorders. Second edition. Totowa, NJ: Humana Press Inc, 2006:121–124.